BioNTech
- Country
- 🇩🇪Germany
- Ownership
- Public
- Employees
- 6.1K
- Market Cap
- $20.7B
- Website
- http://www.biontech.de
- Introduction
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
BioNTech Shuts Down Maryland Cell Therapy Manufacturing Following CAR-T Trial Failure
BioNTech will lay off 63 employees and wind down cell therapy manufacturing at its Gaithersburg, Maryland facility by the end of 2025 following disappointing Phase 1 trial results.
BioNTech to Acquire CureVac for $1.25 Billion to Strengthen mRNA Cancer Immunotherapy Pipeline
BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities.
RFK Jr. Replaces Entire CDC Vaccine Advisory Committee with Eight New Members
Health Secretary Robert F. Kennedy Jr. has replaced all 17 members of the CDC's Advisory Committee on Immunization Practices with eight new appointees, significantly downsizing the committee.
Bristol Myers Squibb Partners with BioNTech in $11.1 Billion Deal for Dual-Target Cancer Immunotherapy
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.
FDA Expands Warning for mRNA COVID-19 Vaccines Due to Heart Side Effect Risk in Young Males
The FDA has ordered Pfizer and Moderna to expand warning labels on their COVID-19 vaccines regarding myocarditis and pericarditis risk, particularly in males aged 16-25, with an incidence rate of 38 cases per million doses.
Breakthrough in Targeted Drug Delivery: Novel Bacteriophage-Loaded Wound Dressings Show Promise for Chronic Infections
Professor Maike Windbergs and her team at Goethe University Frankfurt have developed innovative wound dressings using electrospinning technology that gradually release bacteriophages to combat resistant bacteria in chronic wounds.
Ethris and Lonza Partner to Develop Room-Temperature Stable mRNA Respiratory Vaccines
Ethris and Lonza have formed a strategic partnership to develop spray-dried mRNA vaccines for respiratory diseases that remain stable at room temperature, eliminating cold chain requirements.
CAR-T Cell Therapy Funding Surges to $141.2 Billion as Industry Expands Globally
The CAR-T cell therapy industry has raised over $141.2 billion through various financing mechanisms, with estimates suggesting total industry funding could reach $281.7 billion when including undisclosed deals.
Alnylam Concedes Defeat in COVID-19 Vaccine Patent Dispute with Pfizer and BioNTech
Alnylam Pharmaceuticals has requested a Delaware federal court to end its patent infringement case against Pfizer and BioNTech following an unfavorable patent interpretation ruling.
Big Pharma M&A Activity Surges as Companies Target Undervalued Biotechs Amid Market Recovery
Pharmaceutical M&A activity is experiencing a significant rebound with major deals including Novartis's $1.7 billion acquisition of Regulus Therapeutics and Merck KGaA's $3.9 billion purchase of SpringWorks Therapeutics.